Predictive Oncology Inc. (NASDAQ:POAI) has a beta of 1.98. The stock’s Relative Strength Index (RSI) is 45.86, with weekly volatility at 14.59% and ATR at 0.11. The POAI stock’s 52-week price range has touched low of $0.63 and a $2.30 high. Its shares traded lower over the last trading session, losing -7.39% on 05/19/21. The shares fell to a low of $0.9402 before closing at $0.99. Intraday shares traded counted 1.45 million, which was 50.73% higher than its 30-day average trading volume of 2.94M. POAI’s previous close was $1.07 while the outstanding shares total 36.51M.
Investors have identified the Medical Instruments & Supplies company Predictive Oncology Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $46.75 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Predictive Oncology Inc. (POAI) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 28.2 million total, with 3.26 million as their total liabilities.
POAI were able to record -3.71 million as free cash flow during the 08/16/2021 quarter of the year, this saw their quarterly net cash flow reduce by 26.62 million. In cash movements, the company had a total of -3.32 million as operating cash flow.
Potential earnings growth for Predictive Oncology Inc. (POAI)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/16/2021 quarter of the year, Predictive Oncology Inc. recorded a total of 0.28 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with -5.36% coming in sequential stages and their sales for the 08/16/2021 quarter reducing by -5.0%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 98000.0 trying to sell their products during the last quarter, with the result yielding a gross income of 0.18 million. This allows shareholders to hold on to 36.51M with the recently reported earning now reading -0.11 cents per share. This is a figure that compared to analyst’s prediction for their 08/16/2021.
Is the stock of POAI attractive?
In related news, Chief Executive Officer, Schwartz Carl I. sold 640 shares of the company’s stock in a transaction that recorded on Oct 22. The sale was performed at an average price of 0.85, for a total value of 544. As the sale deal closes, the Director, GABRIEL RICHARD L now bought 4,000 shares of the company’s stock, valued at 3,602. Also, Director, GABRIEL RICHARD L bought 3,000 shares of the company’s stock in a deal that was recorded on Aug 19. The shares were price at an average price of 1.18 per share, with a total market value of 3,527. In the last 6 months, insiders have changed their ownership in shares of company stock by 3.70%.